Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.

Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A.

AIDS Res Hum Retroviruses. 2014 Jan;30(1):17-24. doi: 10.1089/AID.2012.0235. Epub 2013 Sep 17.

2.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
3.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

4.

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC.

Int J Infect Dis. 2013 Oct;17(10):e875-82. doi: 10.1016/j.ijid.2013.02.020. Epub 2013 Apr 15.

5.

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.

Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, Costagliola D; FHDH ANRS CO4.

PLoS One. 2015 Dec 29;10(12):e0144746. doi: 10.1371/journal.pone.0144746. eCollection 2015.

6.

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Perry CM.

Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000. Review.

PMID:
20518583
7.

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.

Hernández-Novoa B, Madrid-Elena N, Dronda F, Pérez-Elias MJ, Casado JL, Pérez-Molina JA, Moreno A, Estébanez M, González J, Zamora J, Moreno S.

J Antimicrob Chemother. 2014 Jul;69(7):1916-9. doi: 10.1093/jac/dku059. Epub 2014 Mar 12.

PMID:
24623833
8.

Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J, Noguera-Julian M, Clotet B, Negredo E, Paredes R.

J Antimicrob Chemother. 2013 Jun;68(6):1382-7. doi: 10.1093/jac/dks539. Epub 2013 Jan 25.

PMID:
23354282
9.

Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.

Ruiz-Mateos E, González-Serna A, Genebat M, Machmach K, Vidal F, Muñoz-Fernández A, Ferrando-Martinez S, Leal M.

Antimicrob Agents Chemother. 2011 Oct;55(10):4664-9. doi: 10.1128/AAC.00753-11. Epub 2011 Aug 1.

10.

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.

Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C; HIV-2 Spanish Study Group.

J Antimicrob Chemother. 2014 Aug;69(8):2191-4. doi: 10.1093/jac/dku119. Epub 2014 Apr 30.

PMID:
24788659
11.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
12.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG.

AIDS Res Hum Retroviruses. 2015 May;31(5):475-8. doi: 10.1089/AID.2014.0223. Epub 2014 Dec 17.

13.

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.

Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

PMID:
23731330
14.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

15.

Virological failure of patients on maraviroc-based antiretroviral therapy.

Raymond S, Maillard A, Amiel C, Peytavin G, Trabaud MA, Desbois D, Bellecave P, Delaugerre C, Soulie C, Marcelin AG, Descamps D, Izopet J; on behalf the ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2015;70(6):1858-64. doi: 10.1093/jac/dkv026. Epub 2015 Feb 19.

PMID:
25700719
16.

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S.

Antiviral Res. 2015 Aug;120:79-84. doi: 10.1016/j.antiviral.2015.05.001. Epub 2015 May 12.

PMID:
25977241
17.

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.

Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O.

J Med Virol. 2006 Oct;78(10):1312-7.

PMID:
16927284
18.

Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

Genebat M, Ruiz-Mateos E, Pulido I, González-Serna A, García-Pergañeda A, Méndez G, Romero-Sánchez MC, Ferrando-Martínez S, Leal M.

Curr HIV Res. 2010 Sep;8(6):482-6.

PMID:
20642436
19.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

20.

[Maraviroc efficacy in clinical studies on the development of the molecule].

Moreno S, Hernández B, Gutiérrez C, Delsol E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:17-22. Review. Spanish.

PMID:
19133217

Supplemental Content

Support Center